SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myelo

SLS

Related stories